Purpose Bone morphogenetic protein (BMP)-2 and -7 are used in patients with long-bone fractures, nonunions and spinal fusions. It is unknown whether their potential systemic bioavailability following local bone administration might affect skeletal metabolism. To answer this question, we examined effects of systemically administered BMP-2 and -7 on bone in a newly developed rat model with a low level of calciotropic hormones. Methods Removal of thyroid and parathyroid glands (TPTx) in rats resulted in a decreased level of calciotropic hormones and subsequent bone loss assessed by micro computed tomography (micro-CT) and measurement of serum bone formation and resorption markers, including osteocalcin, C-telopeptide, osteoprotegerin and receptor activator of nuclear factor kappa-B ligand. Results were complemented with in vitro studies on osteoblast and osteoclast activity by both BMP-2 and -7. The doses used were calculated from published pharmacodynamic studies and bioavailability results from preclinical BMP-2 and -7 studies. Results TPTx resulted in bone loss, which was restored by systemic administration of 10-70 μg/kg of BMP-2 and 10-250 μg/kg of BMP-7. BMP-2 showed a higher capacity for enhancing trabecular microarchitecture, whereas BMP-7 augmented trabecular thickness. In vitro experiments revealed that BMP-2 and -7 when uncoupled increased the number and activity of both osteoblasts and osteoclasts.
Introduction
Bone morphogenetic proteins (BMPs) play an important role in bone and joint regeneration [1] [2] [3] [4] . BMP-2 and -7 with the bovine collagen carrier were approved after randomised, controlled and blinded clinical trials [5, 6] for treating spinal fusions, long-bone nonunions and acute fractures. The osteoinductive ability of BMP-2 and -7 distinguishes them from other available bone grafts and eliminates donor-site morbidity in contrast to autologous bone grafting. Moreover, no adverse events were observed in > 700 patients following randomised clinical trials (RCTs). Both BMP-2-based Infuse and BMP-7-based Osigraft were reported as having side effects and unresolved clinical issues [7, 8] . Specifically, vertebral implant migration and subsidence as a result of early osteolysis, heterotopic ossification and retrograde ejaculation were among registered complications [7, 8] . Similar but more pronounced side effects occurred when BMP-2 and -7 were used for treating long-bone fractures and nonunions, especially at sites where the bone was exposed directly under the skin, such as in distal radial fractures [9] . These results were further supported by preclinical findings of endosteal-site resorption after application of BMP-7 around femoral prostheses in large animals [10] . To avoid similar unwanted results, an appropriate guideline of drug discovery aimed at accelerating bone healing was proposed for nonclinical development [11] .
In formal regulatory nonclinical pharmacodymamic (PD), toxicity and safety evaluation, BMP-2 and -7 showed practically identical properties: bone-healing effect when applied orthotopically with low (≤ 2-3 %) absolute systemic bioavailability, and virtually no systemic toxicity/effects in safety pharmacology studies with systemic administration. However, it is estimated that BMPs applied locally remain active for at least two weeks, suggesting that some amount might remain systemically available for the same period of time. We used a range of BMP-2 and -7 concentrations to mimic their systemic availability, following local application in patients, using a newly developed rat model with a low level of calciotropic hormones.
Materials and methods

Animal model and study protocol
Four-month-old Sprague-Dawley rats, weighting 250 g, were subjected to removal of thyroid and parathyroid glands (TPTx.) Rats were anesthetised with an IP injection of Rompun (Xylapan 0.6 ml/kg) and ketamine (Narketan 0.8 ml/kg). Surgery was performed by a ventral approach: skin and pretracheal muscles were gently dissected, followed by TPTx using a no. 15 surgical blade [12] . Hemostasis was achieved and the wound subsequently closed in anatomical layers. Six animals per experiment underwent sham surgery during which upper muscle layers were dissected but thyroid and parathyroid glands were kept intact. After surgery, rats were kept on regular chow and 1 % calcium gluconate water. Animals were divided into eight groups (n=6): sham; TPTx; TPTx+BMP-2 ,10 μg/kg day; TPTx+BMP-2, 70 μg/kg day; TPTx+BMP-2, 250 μg/kg day; TPTx+BMP-7, 10 μg/kg day; TPTx+BMP-7 ,70 μg/kg day; TPTx+BMP-7, 250 μg/ kg day. Rats were kept under standard conditions for seven days before treatment. Therapy was administered IV for 14 days, starting from seventh day after surgery (Fig. 1) . All experiments and protocols were approved by the Institutional Animal Care Committee of Medical Faculty, University of Zagreb, and the Ministry of Science and Technology.
Recombinant human BMPs
Commercially available recombinant human BMP-2 and -7 (R&D Systems, Minneapolis, MN, USA) were administered IV from day seven to 21 of the experiment according to the protocol at the three different doses.
Biochemical serum parameters Blood (0.5 ml) was collected at various time points by tailvein puncture for serum chemistry (calcium and phosphorus measurements) and to determine bone turnover biomarkers (osteocalcin and C-telopeptide). Animals were lightly anesthetised during the bleed procedure with carbon dioxide/ oxygen (CO 2 /O 2 ). Chemistry endpoints were analysed using a Hitachi 917 autoanalyser (Roche, Indianapolis, IN, USA). Serum bone formation and resorption markers were measured by commercially available kits. Serum concentration of osteocalcin was measured by enzyme-linked immunosorbent assay (ELISA) using rat osteocalcin enzyme immunosorbent assay (EIA) kits (Biomedical Technologies Inc., Stoughton, MA USA). Serum concentration of C-telopeptide was measured by ELISA using RatLaps ELISA kits (Nordic Bioscience Diagnostics, Herlev, Denmark). The osteoprotegerin (OPG) and receptor activator of nuclear factor kappa-B ligand (RANKL) level in serum was measured by ELISA using the Biomedica rat OPG and RANKL ELISA kit (Biomedica, Wien, Austria). The minimum detectable concentration of osteocalcin, cross-linked C-telopeptide (CTx), RANKL and OPG was 1 ng/ml, 2 ng/ml, 0.016 pmol/l and 0.73 pmol/l, respectively.
Micro-CT
The micro computed tomography (micro-CT) 1076 and analysing software used in these experiments were obtained from SkyScan (Kontich, Belgium). The distal femur was scanned in 250 slices, each 18 μm thick, in the dorsoventral direction; 3D bode reconstruction was performed using the triangulation algorithm (NRecon). Trabecular bone parameters, including trabecular bone volume (BV, mm 3 ), trabecular number (Tb.N, 1 mm), trabecular thickness (Tb.Th, μm) and trabecular spacing (Tb.Sp, μm), were directly measured on 3D images.
Cell culture
Bone marrow cells were harvested from femurs and tibias of three month-old rats that previously underwent TPTx. Cells were pooled and plated on 24-well plates at density of 1 × 10 6 cells per well. Differentiation media for osteoclasts contained α-minimum essential medium (α-MEM), 10 % foetal bovine serum (FBS), macrophage-colony-stimulating factor (M-CSF) 20 ng/ml (Sigma Aldrich) and recombinant human soluble RANKL, 20 ng/ml (Sigma Aldrich). BMP-2 (100 ng/ml) and BMP-7 (100 ng/ml) were added to the medium on day one and replaced at every feeding until termination on day six. The cells were fixed with 4 % paraformaldehyde, and adherent osteoclasts were identified by tartrate-resistant acid phosphatase (TRAP) staining using a commercially available kit (Sigma Aldrich). Only osteoclasts with three or more nuclei were counted. For RNA isolation and quantitative real-time polymerase chain reaction (qRT-PCR) analysis, cells were collected in TRI reagent (Life Technologies).
Differentiation medium for osteoblasts was added on day seven and contained α-MEM, 10 % FBS, 10 mM β-glycerophosphate and 50 μg/ml ascorbic acid. The medium was changed every two days until the culture was terminated on day 19. BMP-2 (100 ng/ml) or BMP-7 (100 ng/ml) were added to the medium at every feeding. Osteoblasts were identified by alkaline phosphatase stain using a commercially available kit (Sigma Aldrich). Von Kossa staining was used to determine the mineralised matrix formation. Quantification of the mineralised area was performed using S-form software and expressed as percentage of the mineralised area. qPCR Total RNA from osteoclasts was isolated using TRI reagent (Ambion) according to manufacturer's instructions; 1 μg of total RNA (tRNA) was used in reverse transcription, which was performed using high-capacity complementary DNA (cDNA) reverse transcription kit (Applied Biosystems) and oligo-dT primers for messenger RNA (mRNA) transcription. For gene-expression analysis, quantitative RT-PCR was performed on a Light Cycler (Roche Applied Science) using SYBR Premix Ex Taq TM II (TaKaRa). The comparative C t method (ΔΔC t ) was used for relative quantification of gene expression [13] , with β-actin as a reference gene. Sequences of primers used in PCR were as follows: β-actin FOR: 5'-GCGCAAGT 
Statistical analyses
Data from biochemical, biomechanical and micro-CT analysis as well as in vitro tests are presented as mean ± SD and were analysed using one-way analysis of variance (ANOVA), multivariate ANOVA (MANOVA) or by fitting general linear models, as appropriate. Tukey-Kramer adjustment was used for multiple comparisons. Where needed, data were log transformed.
Results
BMP-2 and -7 enhance bone remodeling in TPTx rats
Following TPTx, animals experienced hypocalcaemia and hyperphosphataemia, as previously described [12] . Parathyroid hormone (PTH), triiodothyronine/thyroxine (T3/ T4), calcitonin and 1,25 (OH) 2 D 3 (1,25-D) plasma levels on the seventh day of the recovery period were very low. Rats were then treated for 14 days with three doses of BMP-2 and -7, and their direct effect on bone in the absence of calciotropic hormones was evaluated (Fig. 1) . T3/T4 and PTH plasma concentrations were significantly decreased, whereas thyrotropin (TSH) was increased due to the negative T3/T4 Fig. 1 Outline of animal experiments. Animals underwent total thyroidectomy-parathyroidectomy (TPTx) or sham surgery. After a 7-day recovery period, the effect of surgery was verified by significantly reduced serum levels of parathyroid hormone (PTH), thyroxine (T4) and 1,25 (OH) 2 feedback loop; 1,25-D level was low as a consequence of PTH deficiency [14] . These changes resulted in low serum calcium levels associated with reduced bone resorption when compared with sham animals (Fig. 2a) . Both BMP-2 and -7 dosedependently increased serum calcium level, but the effect of BMP-2 was significantly pronounced (Fig. 2a) . As expected, the phosphate level was in good correlation with calcium, maintaining the calcium-phosphate product with a similar trend between BMP-2 and -7 doses (Fig. 2b) . Osteocalcin and C-telopeptide, serum markers of bone formation and resorption, were both suppressed in TPTx animals, confirming a low remodeling rate (Fig. 2c, d) . The osteocalcin plasma level in TPTx rats was significantly lower than in sham animals (Fig. 2c) . Neither BMP-2 nor BMP-7 therapy had a significant effect on osteocalcin plasma level (Fig. 2c) . However, there was an overall significant difference between BMP-2 and -7 across all doses in favor of BMP-7 (Fig. 2c) . On the contrary, plasma Ctelopeptide level was lower in TPTx rats with significant positive dose-dependent effects of both BMPs (Fig. 2d) . There was no overall difference between BMP-2 and -7 therapy (Fig. 2d) .
BMP-2 and -7 partially restored bone loss following TPTx Significant bone loss occurred within seven days after TPTx: bone volume/tissue volume (BV/TV) decreased in TPTx rats (9.66 ± 2.24) compared with sham animals (12.02±1.77) (Fig. 3b) . Following 14 days of BMP administration, micro-CT of the distal femur was performed to determine BMP-2 and -7 capacity to compensate for TPTx-induced bone loss; both dose-dependently significantly increased BV/TV in TPTx rats (Fig. 3b) . Tb.N increased by 37 % and 58 %, respectively, in groups treated with 10 and 70 μg/kg of BMP-2, and only a moderate increase was observed when the highest BMP-2 dose was administered (Fig. 3c) . Tb.Th was dosedependently decreased in rats treated with BMP-2 (Fig. 3d) . In TPTx animals treated with 10, 70 and 250 μg/kg of BMP-7, BV/TV increased by 14 %, 38 % and 52 %, respectively, compared with TPTx control animals (Fig. 3b) . Tb.Th was dose-dependently increased in BMP-7-treated animals. Both BMP-2 and BMP-7 lowered soluble RANKL Plasma samples from in vivo studies were analysed for circulating soluble RANK ligand (sRANKL) and OPG at day 14 of therapy. Treatment with both BMP-2 and BMP-7 had no effect on plasma levels of sRANKL (Fig. 4) and OPG (data not shown). Interestingly, TPTx surgery had no influence on sRANKL and OPG at day 7, and the variability of concentrations was high.
In vitro effects of BMP-2 and BMP-7
After six days of treatment, both BMP-2 (100 ng/ml) and BMP-7 (100 ng/ml) increased the number of primary osteoclasts isolated from TPTx rats on day 7 (Fig. 5a) . Surprisingly, BMP-2 and -7 did not stimulate TRAP and cathepsin K expression level (data not shown). Consistent with in vivo results, both BMP-2 and -7 enhanced the differentiation of bone-marrow-derived mesenchymal stem cells towards an osteoblastic phenotype, as evidenced by increased alkaline-phosphatase-positive cells compared with controls (Fig. 5b) . This suggested that BMP-2 and -7 significantly promote both bone formation and resorption in cultured TPTx bone cells. However, their effective outcome in different clinical indications will depend on factors in the specific bone environment, where osteoblasts are coupled to osteoclasts [15] . Therefore, periosteal and muscle satellite progenitors are the major BMP-7 target for uncoupled bone formation activity, mimicking the situation observed in this study.
Discussion
The potential of systemically administered BMP-2 and -7 to enhance bone volume was assessed in the new TPTx rat osteoporotic model. BMP-2 was more beneficial at lower doses, whereas the effect of BMP-7 was increased at higher doses. Moreover, neither BMP-2 or -7 restored bone volume to pre-operative values. The relationship of thyroid hormone to the BMP system is unknown, whereas the role of T3/T4 in bone metabolism has been extensively investigated. The role of BMP in thyrotropin signaling has been suggested, namely, BMP-2, -4, -6 and -7 suppressed TSH-receptor mRNA expression in thyrocytes [16] .
Osteolysis and heterotopic ossification as major side effects of BMP-2 and -7 devices at local sites of implantation have not been fully elucidated. Currently available BMP devices contain milligram amounts of BMP-2 and -7, which form protein aggregates at neutral pH. Those agglomerates usually disseminate in adjacent tissue and subsequently potentiate heterotopic ossification by stimulating uncoupled mesenchymal osteoprogenitor cells outside the bone cavity. Endosteal-site osteolysis was initially noticed when BMP-7 devices were used on sites under the skin with frail muscle envelope. Ekrol et al. unanimously showed the superiority of autogenous bone graft over BMP-7 devices when used in both external and internal fixation of corrective distal radius osteotomy [9] . This was additionally supported with preclinical findings of increased trabecular bone mass in mice without BMP-Ia receptor, which was explained with RANK-RANKL-OPG pathway-suppressed osteoclastogenesis [17] . Osteoblastic effects on osteoclastogenesis were explained by discovering the RANK-RANKL-OPG system, whereas the opposite effect of osteoclasts on osteoblasts remained unclear [18] . It was recently reported that platelet-derived growth factor-BB (PDGF-BB) is a The number of tartrate-resistant acid phosphatase (TRAP)+osteoclasts was determined. Significant difference is indicated with respect to cultivated cells without treatment (a). Alkaline phosphatase staining was used to assess the effect of BMP-2 and -7 on osteoblast differentiation. Area of alkaline phosphatase was measured as described (b) promising candidate for osteoclast-osteoblast interplay, which could complete the coupling circle of bone remodelling [19] . Therefore, the coupling mechanism of osteoblast-osteoclast interaction is probably responsible for orthotopic-site osteolysis in BMP treatment, which overbalanced its osteoinductive ability. BMP-2 enhanced trabecular bone quality, indicating that a low dose was sufficient for this effect. Therefore, large amounts of BMP-2 in commercial devices might increase unwanted side effects.
The expected bioavailability of BMP-2 and -7 used in commercially available bone devices is low, < 5 % of the administered dose, which is eventually close to the highest dose of BMP-2 and the middle dose of BMP-7 used in these experiments. Thus, these results surprisingly suggest that small amounts of BMP-2 and -7 eventually entering the circulation following therapy for bone injuries will not stimulate generalised bone loss. In support of these findings, we previously demonstrated that IV administered recombinant human (rh)BMP-6 restored lost bone by stimulating bone formation in aged, osteoporotic, ovariectomised rats [20] .
In conclusion, systemic administration of BMP-2 and -7 for 14 days in TPTx rats proved their osteoinductive potential without any side effects. Osteolytic effect observed in human BMP devices containing BMP-2 and -7 used on the orthotopic site will be related and dependent primarily on the bone-cell microenvironment and preservation of surrounding tissues, mainly periosteum and skeletal muscle satellite cells. As there is a great medical need for a more effective and safe treatment option in bone-defect regeneration, we lately introduced a novel bone-healing principle based on using low levels of BMP-6 and a carrier prepared from the patient's own blood [15] .
